S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

ImmunoGen (IMGN) Stock Forecast, Price & News

+0.05 (+1.42%)
(As of 05/20/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
5.19 million shs
Average Volume
4.37 million shs
Market Capitalization
$789.53 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive IMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter.

ImmunoGen logo

About ImmunoGen

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$69.86 million
Book Value
$1.39 per share


Net Income
$-139.30 million
Net Margins
Pretax Margin




Free Float
Market Cap
$789.53 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

1.96 out of 5 stars

Medical Sector

640th out of 1,416 stocks

Pharmaceutical Preparations Industry

296th out of 677 stocks

Analyst Opinion: 3.3Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

ImmunoGen (NASDAQ:IMGN) Frequently Asked Questions

Is ImmunoGen a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ImmunoGen stock.
View analyst ratings for ImmunoGen
or view top-rated stocks.

When is ImmunoGen's next earnings date?

ImmunoGen is scheduled to release its next quarterly earnings announcement on Friday, July 29th 2022.
View our earnings forecast for ImmunoGen

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) posted its quarterly earnings data on Friday, May, 6th. The biotechnology company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.11. The biotechnology company had revenue of $38.10 million for the quarter, compared to analyst estimates of $20.84 million. ImmunoGen had a negative net margin of 140.30% and a negative trailing twelve-month return on equity of 66.56%. The firm's revenue for the quarter was up 142.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.17) earnings per share.
View ImmunoGen's earnings history

What guidance has ImmunoGen issued on next quarter's earnings?

ImmunoGen updated its FY 2022 earnings guidance on Monday, May, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $75.00 million-$85.00 million, compared to the consensus revenue estimate of $84.98 million.

What price target have analysts set for IMGN?

4 brokerages have issued 1 year price targets for ImmunoGen's shares. Their forecasts range from $5.00 to $18.00. On average, they expect ImmunoGen's stock price to reach $10.25 in the next year. This suggests a possible upside of 186.3% from the stock's current price.
View analysts' price targets for ImmunoGen
or view top-rated stocks among Wall Street analysts.

Who are ImmunoGen's key executives?
ImmunoGen's management team includes the following people:
  • Mr. Mark Joseph Enyedy, Pres, CEO & Director (Age 58, Pay $1.24M)
  • Ms. Susan Altschuller Ph.D., Sr. VP & CFO (Age 39, Pay $537.53k)
  • Dr. Anna Berkenblit M.D., MM.Sc, Sr. VP & Chief Medical Officer (Age 52, Pay $647.28k)
  • Ms. Stacy A. Coen, Sr. VP & Chief Bus. Officer (Age 51, Pay $547.66k)
  • Ms. Kristen Harrington-Smith, Sr. VP & Chief Commercial Officer (Age 49, Pay $562.52k)
  • Ms. Renee Lentini, VP of Fin. & Principal Accounting Officer (Age 44)
  • Ms. Courtney O'Konek, Sr. Director of Corp. Communications & Investor Relations
  • Mr. Joseph J. Kenny, VP, Acting Gen. Counsel, Intellectual Property & Sec.
  • Ms. Audrey Bergan, Sr. VP & Chief HR Officer
  • Dr. Theresa G. Wingrove, Sr. VP of Regulatory Affairs & Quality (Age 64)
What is Mark J. Enyedy's approval rating as ImmunoGen's CEO?

16 employees have rated ImmunoGen CEO Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among ImmunoGen's employees.

What other stocks do shareholders of ImmunoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX).

What is ImmunoGen's stock symbol?

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

Who are ImmunoGen's major shareholders?

ImmunoGen's stock is owned by a variety of institutional and retail investors. Top institutional investors include RA Capital Management L.P. (9.86%), BlackRock Inc. (7.45%), Vanguard Group Inc. (7.02%), State Street Corp (6.22%), Wellington Management Group LLP (5.92%) and Clearbridge Investments LLC (2.50%).
View institutional ownership trends for ImmunoGen

Which institutional investors are selling ImmunoGen stock?

IMGN stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co., Wellington Management Group LLP, Clearbridge Investments LLC, Goldman Sachs Group Inc., Citigroup Inc., Rhenman & Partners Asset Management AB, Principal Financial Group Inc., and Metropolitan Life Insurance Co NY.
View insider buying and selling activity for ImmunoGen
or view top insider-selling stocks.

Which institutional investors are buying ImmunoGen stock?

IMGN stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Deerfield Management Company L.P. Series C, BlackRock Inc., RA Capital Management L.P., Sectoral Asset Management Inc., Granahan Investment Management LLC, Vanguard Group Inc., and UBS Group AG.
View insider buying and selling activity for ImmunoGen
or or view top insider-buying stocks.

How do I buy shares of ImmunoGen?

Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmunoGen's stock price today?

One share of IMGN stock can currently be purchased for approximately $3.58.

How much money does ImmunoGen make?

ImmunoGen has a market capitalization of $789.53 million and generates $69.86 million in revenue each year. The biotechnology company earns $-139.30 million in net income (profit) each year or ($0.600010) on an earnings per share basis.

How many employees does ImmunoGen have?

ImmunoGen employs 106 workers across the globe.

Does ImmunoGen have any subsidiaries?

The following companies are subsidiares of ImmunoGen: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..

When was ImmunoGen founded?

ImmunoGen was founded in 1981.

What is ImmunoGen's official website?

The official website for ImmunoGen is www.immunogen.com.

How can I contact ImmunoGen?

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at (781) 895-0600, via email at [email protected], or via fax at 781-895-0611.

This page was last updated on 5/21/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.